Abstract: A method for producing an antibody-drug conjugate in which a drug-linker represented by formula (1) (wherein A represents the connecting position to an antibody) is conjugated to the antibody via a thioether bond, wherein the method comprising the steps of: (i) reducing the antibody with a reducing agent; (ii) reacting a drug-linker intermediate with the antibody reduced in step (i); (iii) adding a reagent having a thiol group to react with the residual drug-linker intermediate in step (ii); and then (iv) removing by-products derived from the drug-linker intermediate through ultrafiltration using a buffer solution containing a salt consisting of a strong acid and a strong base, and a method for producing a pharmaceutical composition containing the antibody-drug conjugate.

Abstract: The present invention provides a method for producing a 1-biphenylmethylimidazole compound having superior angiotensin II receptor antagonistic activity, or an intermediate thereof. The present invention provides a method for producing a compound having the formula (5) (R1, Ra: H, an alkyl group) by oxidizing a compound having the formula (1) (Ra: H, an alkyl group) using an oxidizing agent in the presence of a radical initiation reagent, and then reacting with an ammonia-generating reagent and a compound having the formula R1CHO(R1: H, an alkyl group) or a compound having the formula R1C(ORb)3 (R1: H, an alkyl group; Rb: an alkyl group).

Abstract: The present invention provides a method for producing a 1-biphenylmethylimidazole compound having superior angiotensin II receptor antagonistic activity, or an intermediate thereof. The present invention provides a method for producing a compound having the formula (5) (R1, Ra: H, an alkyl group) by oxidizing a compound having the formula (1) (Ra: H, an alkyl group) using an oxidizing agent in the presence of a radical initiation reagent, and then reacting with an ammonia-generating reagent and a compound having the formula R1CHO(R1: H, an alkyl group) or a compound having the formula R1C(ORb)3 (R1: H, an alkyl group; Rb: an alkyl group).

Abstract: The present invention relates to a method for producing a quinolone compound having high antibacterial activity and high safety, at high yield and in a simple manner. A quinolonecarboxylic acid derivative (1) of interest is produced through a one-pot manner by reacting a compound (2) with a salt of a cyclic amine (3) and with a boron derivative in a solvent in the presence of a base.

Abstract: The present invention relates to a method for producing a quinolone compound having high antibacterial activity and high safety, at high yield and in a simple manner. A quinolonecarboxylic acid derivative (1) of interest is produced through a one-pot manner by reacting a compound (2) with a salt of a cyclic amine (3) and with a boron derivative in a solvent in the presence of a base.

Abstract: A compound having an action of suppressing platelet aggregation is provided. This compound also exhibits excellent physical properties and oral absorbability. This compound is represented by formula (Ib): Its production method is also provided.

Abstract: A method of producing 2-fluorocyclopropane-1-carboxylic acid ester, which comprise by allowing a compound represented by the following formula (1): wherein X represents a chlorine atom, a bromine atom or an iodine atom; and R1 represents an alkyl group having 1 to 8 carbon atoms, an aryl group having 6 to 12 carbon atoms, an alkenyl group having 2 to 8 carbon atoms, or an aralkyl group composed of an aryl group having 6 to 12 carbon atoms and an alkylene group having 1 to 6 carbon atoms; to react with a reducing agent in the presence of a phase transfer catalyst. According to the production method of the present invention, the reaction time of dehalogenation can be greatly shortened.

Abstract: A method of producing 2-fluorocyclopropane-1-carboxylic acid ester, which comprise by allowing a compound represented by the following formula (1): wherein X represents a chlorine atom, a bromine atom or an iodine atom; and R1 represents an alkyl group having 1 to 8 carbon atoms, an aryl group having 6 to 12 carbon atoms, an alkenyl group having 2 to 8 carbon atoms, or an aralkyl group composed of an aryl group having 6 to 12 carbon atoms and an alkylene group having 1 to 6 carbon atoms; to react with a reducing agent in the presence of a phase transfer catalyst. According to the production method of the present invention, the reaction time of dehalogenation can be greatly shortened.